Vivacta Bio
Vivacta is a GRIT in vivo CAR-T platform spinout developing CD19 mRNA/tLNP candidate GT801. A first-in-human study is registered as NCT07205315. Its October 2026 U.S. orphan designation for AIHA is not approval or proof of efficacy; GT801 is shared with the GRIT profile.
Corporate information
- Company entity
- Vivacta Bio
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- PrivateSeries A + A+ (combined disclosure) ↗
- Official corporate reference
- https://www.prnewswire.com/news-releases/vivacta-bio-and-grit-bio-announce-fda-orphan-drug-designation-for-in-vivo-car-t-therapy-gt801-in-autoimmune-hemolytic-anemia-302911806.html ↗
- Latest financing / award identified
- 2026-04-29 · Series A + A+ (combined disclosure) · Over US$50 million across Series A and A+; not a single-round amount ↗
- LinkedIn company page
- Independent company page not verified
Disclosed equity event found in this review; not a claim that no later undisclosed event exists.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Vivacta is a GRIT in vivo CAR-T platform spinout developing CD19 mRNA/tLNP candidate GT801. A first-in-human study is registered as NCT07205315. Its October 2026 U.S. orphan designation for AIHA is not approval or proof of efficacy; GT801 is shared with the GRIT profile.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Vivacta / GRIT company-issued announcement; distributor is not the company identity
- Vivacta Bio — supporting primary disclosure
- Company financing announcement